Evidence map›Paper›PMID 26432383›Full record

GuidelineHaematologica2015

European Myeloma Network guidelines for the management of multiple myeloma-related complications.

Evangelos Terpos, Martina Kleber, Monika Engelhardt, Sonja Zweegman, Francesca Gay, Efstathios Kastritis, Niels W C J van de Donk, Benedetto Bruno, Orhan Sezer, Annemiek Broijl and 14 more

Open access · goldAbstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Haematologica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 162 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
162citing papers in PubMed, 6 pooled it
25.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

162 citing papers in PubMed, 6 syntheses or guidelines pooled it, 391 citations in OpenAlex.

  1. EANM guidelines on the use of [European journal of nuclear medicine and molecular imaging · 2024
    Guideline
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Prospective Evaluation of Magnetic Resonance Imaging and [Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017
    Trial
  13. Trial
  14. Trial
  15. Review
  16. Review
  17. Article
  18. Review
  19. Management of bone health in cancer survivorship: a systematic review of clinical guidelines.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
    Review
  20. Article

102 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 17 institutions in 9 countries.

Evangelos TerposDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Greece eterpos@med.uoa.gr.
Martina KleberDepartment of Hematology and Oncology, University of Freiburg Medical Center, Germany Clinic for Internal Medicine, University Hospital Basel, Switzerland.
Monika EngelhardtDepartment of Hematology and Oncology, University of Freiburg Medical Center, Germany.
Sonja ZweegmanDepartment of Hematology, VU University Medical Center, Amsterdam, the Netherlands.
Francesca GayDivision of Hematology, S. Giovanni Battista Hospital, University of Turin, Italy.
Efstathios KastritisDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Greece.
Niels W C J van de DonkDepartment of Hematology, University Medical Center, Utrecht, the Netherlands.
Benedetto BrunoDivision of Hematology, S. Giovanni Battista Hospital, University of Turin, Italy.
Orhan SezerDepartment of Hematology, Memorial Sisli Hospital, Istanbul, Turkey.
Annemiek BroijlDepartment of Hematology, Erasmus University Medical Center Rotterdam, the Netherlands.
Sara BringhenDivision of Hematology, S. Giovanni Battista Hospital, University of Turin, Italy.
Meral BeksacDepartment of Hematology, Ankara University, Turkey.
Alessandra LaroccaDivision of Hematology, S. Giovanni Battista Hospital, University of Turin, Italy.
Roman HajekDepartment of Hemato-Oncology, University Hospital Ostrava and Faculty of Medicine OU, Ostrava, Czech Republic.
Pellegrino MustoCentro di Riferimento Oncologico della Basilicata, Istituto di Ricovero e Cura a Carattere Scientifico, Rionero in Vulture, Italy.
Hans Erik JohnsenDepartment of Hematology, Aalborg University Hospital, Denmark.
Fortunato MorabitoDepartment of Hematology, Azienda Ospedaliera dell'Annunziata, Cosenza, Italy.
Heinz LudwigDepartment of Medicine I, Center of Oncology, Hematology and Palliative Care, Wilhelminenspital, Vienna, Austria.
Michele Cavo"Seràgnoli" Institute of Hematology and Medical Oncology, University of Bologna, Italy.
Hermann EinseleDepartment of Internal Medicine II, University Hospital Würburg, Würzburg, Germany.
Pieter SonneveldDepartment of Hematology, Erasmus University Medical Center Rotterdam, the Netherlands.
Meletios A DimopoulosDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Greece.
Antonio PalumboDivision of Hematology, S. Giovanni Battista Hospital, University of Turin, Italy.
European Myeloma Network
National and Kapodistrian University of Athens · GRUniversity of Turin · ITAzienda Ospedaliero Universitaria San Giovanni Battista · ITErasmus MC · NLAalborg University Hospital · DKAmsterdam UMC Location VUmc · NLAnkara University · TRCentro di Riferimento Oncologico della Basilicata · ITIstituto Oncologico Romagnolo · ITMemorial Sisli Hospital · TROspedale Annunziata di Cosenza · ITUniversitätsklinikum Würzburg · DEUniversity Hospital Ostrava · CZUniversity Medical Center Freiburg · DEUniversity Medical Center Utrecht · NLUniversity of Freiburg · DEWilhelminen Hospital · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The European Myeloma Network provides recommendations for the management of the most common complications of multiple myeloma. Whole body low-dose computed tomography is more sensitive than conventional radiography in depicting osteolytic disease and thus we recommend it as the novel standard for the detection of lytic lesions in myeloma (grade 1A). Myeloma patients with adequate renal function and bone disease at diagnosis should be treated with zoledronic acid or pamidronate (grade 1A). Symptomatic patients without lytic lesions on conventional radiography can be treated with zoledronic acid (grade 1B), but its advantage is not clear for patients with no bone involvement on computed tomography or magnetic resonance imaging. In asymptomatic myeloma, bisphosphonates are not recommended (grade 1A). Zoledronic acid should be given continuously, but it is not clear if patients who achieve at least a very good partial response benefit from its continuous use (grade 1B). Treatment with erythropoietic-stimulating agents may be initiated in patients with persistent symptomatic anemia (hemoglobin <10g/dL) in whom other causes of anemia have been excluded (grade 1B). Erythropoietic agents should be stopped after 6-8 weeks if no adequate hemoglobin response is achieved. For renal impairment, bortezomib-based regimens are the current standard of care (grade 1A). For the management of treatment-induced peripheral neuropathy, drug modification is needed (grade 1C). Vaccination against influenza is recommended; vaccination against streptococcus pneumonia and hemophilus influenza is appropriate, but efficacy is not guaranteed due to suboptimal immune response (grade 1C). Prophylactic aciclovir (or valacyclovir) is recommended for patients receiving proteasome inhibitors, autologous or allogeneic transplantation (grade 1A).

Indexed as

Disease ManagementAnemiaBone DiseasesHumansInfectionsKidney DiseasesMultiple MyelomaPain ManagementPeripheral Nervous System DiseasesVenous Thromboembolism

Identifiers

PMID26432383
PMCPMC4591757
OpenAlexW2172421250

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.